Kane Biotech

Kane Biotech Net Debt

The Net Debt of Kane Biotech (KNE.V) as of Nov 5, 2026 is 617,159.00 CAD. In the previous year, Net Debt was 958,238.00 CAD — a change of -35.59% (lower).

Net Debt

617,159.00CAD

YoY

-35.59%

Last updated:

Net Debt of Kane Biotech is 2025 617,159.00 CAD. Net Debt of Kane Biotech was 2024 958,238.00 CAD. It decreases by -35.59% lower compared to the previous year.

The Kane Biotech Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
424,575.00 CAD
Jan 1, 2019
-664,313.00 CAD
Jan 1, 2020
1.24 M CAD
Jan 1, 2021
3.56 M CAD
Jan 1, 2022
5.75 M CAD
Jan 1, 2023
8.46 M CAD
Jan 1, 2024
958,238.00 CAD
Jan 1, 2025
617,159.00 CAD
The Kane Biotech Net Debt history
YEARNet DebtYoY
617,159.00CAD-35.59%
958,238.00CAD-88.68%
8.46 MCAD+47.12%
5.75 MCAD+61.49%
3.56 MCAD+186.78%
1.24 MCAD-286.96%
-664,313.00CAD-256.47%
424,575.00CAD-120.78%
-2.04 MCAD+686.99%
-259,572.00CAD-180.53%
322,339.00CAD-162.27%
-517,661.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kane Biotech Stock analysis

What does Kane Biotech do? Kane Biotech, Inc. generates revenue through its portfolio of biotechnology products designed to prevent and remove microbial biofilms. The company commercializes StrixNB, DispersinB, Aledex, bluestem, silkstem, goldstem, coactiv+, and DermaKB Biofilm, with specific focus on the Wound Care & Surgical division developing DispersinB for chronic wound care. The bluestem product line targets animal health markets with water additives, chews, spray, and dental wipes, while Coactiv+ and DispersinB Gel are in development for antimicrobial wound rinse and prosthetic joint infection applications. Additional products include Scalp Detoxifier, Shampoo, and Shampoo Bars for consumer use. Kane Biotech serves animal health markets through its bluestem product line, which includes water additives, chews, spray, and dental wipes. The Wound Care & Surgical division targets medical applications, focusing on DispersinB for chronic wounds and developing Coactiv+ for antimicrobial wound rinse and surgical hydrogel. Consumer products like Scalp Detoxifier, Shampoo, and Shampoo Bars cater to personal care segments. The company's development-stage products such as Coactiv+ antimicrobial surgical hydrogel and DispersinB Gel for prosthetic joint infection represent future revenue streams. The company's primary markets include animal health for bluestem products, medical applications for Wound Care & Surgical division, and consumer personal care for Scalp Detoxifier and Shampoo products. DispersinB is central to the medical division, while bluestem dominates the animal health segment. Development-stage products like Coactiv+ and DispersinB Gel are positioned to address unmet needs in wound care and prosthetic infections, expanding the company's market reach into specialized medical and consumer health segments. Kane Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kane Biotech stock

Net Debt of Kane Biotech is 617,159.00 CAD in 2025.

Net Debt of Kane Biotech changed from 958,238.00 CAD to 617,159.00 CAD, representing a -35.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Kane Biotech since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Kane Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Kane Biotech

All Key Metrics — Kane Biotech